Literature DB >> 30234399

Management of primary refractory acute myeloid leukemia in the era of targeted therapies.

Christine M McMahon1, Alexander E Perl1.   

Abstract

Primary refractory acute myeloid leukemia (AML), or primary induction failure, represents a continued challenge in clinical management. This review presents an overview of primary refractory disease and a discussion of risk factors for induction failure, including current evidence regarding the impact of karyotype and molecular mutation status on responsiveness to chemotherapy. We review the evidence for various treatment options for refractory AML including salvage chemotherapy regimens, allogeneic hematopoietic stem cell transplantation, targeted agents, and non-intensive therapies such as hypomethylating agents. A therapeutic approach to this patient population is presented, and several new and emerging therapies are reviewed.

Entities:  

Keywords:  Acute myeloid leukemia primary refractory; induction failure salvage chemotherapy

Mesh：

Substances：

Year:  2018        PMID： 30234399      PMCID： PMC6945493          DOI： 10.1080/10428194.2018.1504937

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


  119 in total

1.  First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.

Authors:  Eric J Feldman; Jeffrey E Lancet; Jonathan E Kolitz; Ellen K Ritchie; Gail J Roboz; Alan F List; Steven L Allen; Ekatherine Asatiani; Lawrence D Mayer; Christine Swenson; Arthur C Louie
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

2.  Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia.

Authors:  Pamela S Becker; Hagop M Kantarjian; Frederick R Appelbaum; Barry Storer; Sherry Pierce; Jianqin Shan; Stephan Faderl; Elihu H Estey
Journal:  Haematologica       Date:  2012-07-16       Impact factor: 9.941

3.  Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.

Authors:  M Wattad; D Weber; K Döhner; J Krauter; V I Gaidzik; P Paschka; M Heuser; F Thol; T Kindler; M Lübbert; H R Salih; A Kündgen; H-A Horst; P Brossart; K Götze; D Nachbaur; C-H Köhne; M Ringhoffer; G Wulf; G Held; H Salwender; A Benner; A Ganser; H Döhner; R F Schlenk
Journal:  Leukemia       Date:  2017-01-19       Impact factor: 11.528

4.  Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience.

Authors:  Bruno C Medeiros; Megan Othus; Min Fang; Diane Roulston; Frederick R Appelbaum
Journal:  Blood       Date:  2010-06-18       Impact factor: 22.113

5.  A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study.

Authors:  C Karanes; K J Kopecky; D R Head; M R Grever; H E Hynes; E H Kraut; R H Vial; A Lichtin; S Nand; W E Samlowski; F R Appelbaum
Journal:  Leuk Res       Date:  1999-09       Impact factor: 3.156

6.  Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.

Authors:  Daniel J Weisdorf; Heather R Millard; Mary M Horowitz; Parvinder S Hyare; Richard Champlin; Vincent Ho; Marco Mielcarek; Andrew Rezvani; Keith Stockerl-Goldstein; Hanna J Khoury; Marcos De Lima; Wael Saber; Brenda Sandmaier; Mei Jie Zhang; Mary Eapen
Journal:  Cancer       Date:  2017-01-24       Impact factor: 6.860

7.  Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.

Authors:  Farhad Ravandi; Mona Lisa Alattar; Michael R Grunwald; Michelle A Rudek; Trivikram Rajkhowa; Mary Ann Richie; Sherry Pierce; Naval Daver; Guillermo Garcia-Manero; Stefan Faderl; Aziz Nazha; Marina Konopleva; Gautam Borthakur; Jan Burger; Tapan Kadia; Sara Dellasala; Michael Andreeff; Jorge Cortes; Hagop Kantarjian; Mark Levis
Journal:  Blood       Date:  2013-04-23       Impact factor: 22.113

8.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

Authors:  Maria E Figueroa; Omar Abdel-Wahab; Chao Lu; Patrick S Ward; Jay Patel; Alan Shih; Yushan Li; Neha Bhagwat; Aparna Vasanthakumar; Hugo F Fernandez; Martin S Tallman; Zhuoxin Sun; Kristy Wolniak; Justine K Peeters; Wei Liu; Sung E Choe; Valeria R Fantin; Elisabeth Paietta; Bob Löwenberg; Jonathan D Licht; Lucy A Godley; Ruud Delwel; Peter J M Valk; Craig B Thompson; Ross L Levine; Ari Melnick
Journal:  Cancer Cell       Date:  2010-12-09       Impact factor: 38.585

9.  The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo.

Authors:  E Todisco; F Ciceri; E Oldani; C Boschini; C Micò; M T Vanlint; I Donnini; F Patriarca; P E Alessandrino; F Bonifazi; W Arcese; W Barberi; P Marenco; E Terruzzi; S Cortelazzo; S Santarone; A Proia; P Corradini; E Tagliaferri; S Falcioni; G Irrera; L Dallanegra; L Castagna; A Santoro; A Camboni; N Sacchi; A Bosi; A Bacigalupo; A Rambaldi
Journal:  Leukemia       Date:  2013-07-09       Impact factor: 11.528

10.  Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.

Authors:  Alexander E Perl; Jessica K Altman; Jorge Cortes; Catherine Smith; Mark Litzow; Maria R Baer; David Claxton; Harry P Erba; Stan Gill; Stuart Goldberg; Joseph G Jurcic; Richard A Larson; Chaofeng Liu; Ellen Ritchie; Gary Schiller; Alexander I Spira; Stephen A Strickland; Raoul Tibes; Celalettin Ustun; Eunice S Wang; Robert Stuart; Christoph Röllig; Andreas Neubauer; Giovanni Martinelli; Erkut Bahceci; Mark Levis
Journal:  Lancet Oncol       Date:  2017-06-20       Impact factor: 41.316
View more
  2 in total

1.  European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response.

Authors:  K H Begna; J Kittur; N Gangat; H Alkhateeb; M S Patnaik; A Al-Kali; M A Elliott; W J Hogan; M R Litzow; A Pardanani; C A Hanson; R P Ketterling; A Tefferi
Journal:  Blood Cancer J       Date:  2022-01-17       Impact factor: 11.037

2.  A clinically applicable gene expression-based score predicts resistance to induction treatment in acute myeloid leukemia.

Authors:  Christian Moser; Vindi Jurinovic; Sabine Sagebiel-Kohler; Bianka Ksienzyk; Aarif M N Batcha; Annika Dufour; Stephanie Schneider; Maja Rothenberg-Thurley; Cristina M Sauerland; Dennis Görlich; Wolfgang E Berdel; Utz Krug; Ulrich Mansmann; Wolfgang Hiddemann; Jan Braess; Karsten Spiekermann; Philipp A Greif; Sebastian Vosberg; Klaus H Metzeler; Jörg Kumbrink; Tobias Herold
Journal:  Blood Adv       Date:  2021-11-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.